AZD5985 Single Ascending Dose Study
- Registration Number
- NCT00967356
- Lead Sponsor
- AstraZeneca
- Brief Summary
The aims of this study are to assess the safety, tolerability and pharmacokinetics of single ascending oral doses of AZD5985 in healthy male subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 72
Inclusion Criteria
- Provision of signed, written and dated informed consent prior to any study specific procedure
- Healthy male subjects aged 18 to 45 years (inclusive)
- Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
- Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for >6 months prior to study start
Exclusion Criteria
- History or presence of any clinically significant disease or disorder in the opinion of the investigator
- Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator
- Participation in another investigational drug study within 3 months before Visit 2 or participation in a methodological study (no drug) 1 month prior to Visit 2
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A AZD5985 AZD5985 B Placebo Placebo
- Primary Outcome Measures
Name Time Method Safety variables (ECG, adverse events, blood pressure, pulse, body temp, safety lab) Frequent sampling occasions during study days
- Secondary Outcome Measures
Name Time Method Pharmacokinetic variables Frequent sampling occasions during study days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets of AZD5985 in phase I clinical trials for healthy subjects?
How does AZD5985 compare to other kinase inhibitors in terms of safety and pharmacokinetics?
What adverse events are associated with AZD5985 in early-phase human trials?
Are there biomarkers that correlate with AZD5985's pharmacokinetic profile in healthy volunteers?
What is the mechanism of action of AZD5985 and its relevance to AstraZeneca's drug development pipeline?
Trial Locations
- Locations (1)
Research Site
🇸🇪Goteborg, Sweden
Research Site🇸🇪Goteborg, Sweden